company background image
AVXL

Anavex Life Sciences NasdaqGS:AVXL Stock Report

Last Price

US$8.82

Market Cap

US$687.6m

7D

-22.4%

1Y

-50.8%

Updated

30 Nov, 2022

Data

Company Financials +
AVXL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AVXL Stock Overview

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.

Anavex Life Sciences Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anavex Life Sciences
Historical stock prices
Current Share PriceUS$8.82
52 Week HighUS$20.24
52 Week LowUS$7.13
Beta0.79
1 Month Change-27.53%
3 Month Change-8.60%
1 Year Change-50.75%
3 Year Change191.09%
5 Year Change145.00%
Change since IPO13,129.74%

Recent News & Updates

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Oct 01
We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Recent updates

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Oct 01
We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Jun 17
We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Mar 03
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Nov 16
Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Jul 30
Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Apr 16
Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Jan 01
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Shareholder Returns

AVXLUS BiotechsUS Market
7D-22.4%2.3%1.5%
1Y-50.8%-10.2%-14.8%

Return vs Industry: AVXL underperformed the US Biotechs industry which returned -15.2% over the past year.

Return vs Market: AVXL underperformed the US Market which returned -18.9% over the past year.

Price Volatility

Is AVXL's price volatile compared to industry and market?
AVXL volatility
AVXL Average Weekly Movement13.1%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: AVXL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: AVXL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200438Chris Misslinghttps://www.anavex.com

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases.

Anavex Life Sciences Corp. Fundamentals Summary

How do Anavex Life Sciences's earnings and revenue compare to its market cap?
AVXL fundamental statistics
Market CapUS$687.62m
Earnings (TTM)-US$47.98m
Revenue (TTM)n/a

0.0x

P/S Ratio

-14.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVXL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$47.98m
Earnings-US$47.98m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.62
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did AVXL perform over the long term?

See historical performance and comparison